ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear, odorless ...
CHICAGO — The Food and Drug Administration has approved a new pocket-sized packet option for a testosterone-replacement therapy made by AbbVie, the drug maker said Friday. AbbVie announced the ...
The FDA has approved AndroGel (testosterone gel; Abbott) 1.62% for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, including ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
Active ingredient: Testosterone 10 mg/0.5 g actuation; metered-dose pump; topical gel. Indication: Primary hypogonadism. Hypogonadotropic hypogonadism. Pharmacology: Fortesta is a topical gel ...
The purpose of the present study was to evaluate the efficacy and safety of 50 mg/day of TTG, applied on non-scrotal skin, for hypogonadal men in Taiwan. Although TTG has been shown to be effective in ...
Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received tentative approval from the US Food & Drug Administration (FDA) for its ...
Hypogonadism is common and increases with age in men as serum testosterone levels gradually decline. Estimates of the prevalence of androgen deficiency among men 40–70 years of age range from 12 to 45 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results